Dr. Svilenov is an Associate Professor of Biopharmaceutical Technology at the Technical University of Munich (TUM). His research focuses on the development, formulation, and manufacturing of biotherapeutics. In 2024, he was awarded an ERC grant to advance novel antibody-based therapeutics.
Prior to his appointment at TUM, Dr. Svilenov served as a Professor at Ghent University. He previously conducted postdoctoral research in the group of Prof. Johannes Buchner at TUM, supported by a Peter and Traudl Engelhorn Fellowship and a grant from the Else Kröner-Fresenius Foundation.
Dr. Svilenov earned his PhD under the supervision of Prof. Gerhard Winter at the Ludwig Maximilian University of Munich, funded by a Marie Skłodowska-Curie Fellowship. He completed his doctoral studies with the highest honors (summa cum laude) and received the AbbVie Prize and the Carl-Wilhelm-Scheele Award from the German Pharmaceutical Society in recognition of his work.